We are live on ! Find out more
GEVA

SYNAGEVA BIOPHARMA CORP COM STK (DE)
GEVA

Delisted

GEVA was delisted on the 22nd of June, 2015.

Back to rankings

115 hedge funds and large institutions have $2.68B invested in SYNAGEVA BIOPHARMA CORP COM STK (DE) in 2014 Q1 according to their latest regulatory filings, with 39 funds opening new positions, 41 increasing their positions, 28 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

457% more first-time investments, than exits

New positions opened: 39 | Existing positions closed: 7

46% more repeat investments, than reductions

Existing positions increased: 41 | Existing positions reduced: 28

37% more funds holding

Funds holding: 84 → 115 (+31)

35% more capital invested

Capital invested by funds: $1.98B → $2.68B (+$697M)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

64% less call options, than puts

Call options by funds: $13.9M | Put options by funds: $38.7M

Holders
115
Holders Change
+31
Holders Change %
+36.9%
% of All Funds
3.32%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.06%
New
39
Increased
41
Reduced
28
Closed
7
Calls
$13.9M
Puts
$38.7M
Net Calls
-$24.8M
Net Calls Change
-$29.5M

Top Buyers

Rank Fund Capital Flow
1
Capital World Investors
Capital World Investors
California
+$44.7M
2
BBA
Baker Bros. Advisors
New York
+$34.7M
3
Invesco
Invesco
Georgia
+$31.9M
4
DM
Deerfield Management
New York
+$29.4M
5
Capital Research Global Investors
Capital Research Global Investors
California
+$24.9M

Top Sellers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
-$32.4M
2
SAM
Sectoral Asset Management
Quebec, Canada
-$25.3M
3
JHIU
Janus Henderson Investors US
Colorado
-$20.4M
4
Lord, Abbett & Co
Lord, Abbett & Co
New Jersey
-$14.1M
5
FAM
Fred Alger Management
New York
-$11.5M
Name Holding Trade Value Shares
Change 		Change in
Stake
PP
51
PDT Partners
New York
$2.54M +$2.83M +30,588 New
TA
52
Teachers Advisors
New York
$2.37M +$210K +2,270 +9%
MOACM
53
Mutual of America Capital Management
New York
$2.17M +$712K +7,700 +42%
DIA
54
Denver Investment Advisors
Colorado
$2.11M +$2.35M +25,439 New
PCM
55
Pentwater Capital Management
Florida
$2.07M +$2.31M +25,000 New
BA
56
BlackRock Advisors
Delaware
$2.07M -$9.06M -97,979 -80%
CS
57
Credit Suisse
Switzerland
$2.02M +$714K +7,726 +46%
DCM
58
Driehaus Capital Management
Illinois
$2.02M +$2.26M +24,392 New
MAA
59
Managed Account Advisors
New Jersey
$1.85M +$1.22M +13,245 +146%
Swiss National Bank
60
Swiss National Bank
Switzerland
$1.73M +$536K +5,800 +38%
GL
61
GLG LLC
New York
$1.71M +$1.91M +20,622 New
DekaBank Deutsche Girozentrale
62
DekaBank Deutsche Girozentrale
Germany
$1.55M +$106K +1,150 +7%
RhumbLine Advisers
63
RhumbLine Advisers
Massachusetts
$1.42M +$7.4K +80 +0.5%
American Century Companies
64
American Century Companies
Missouri
$1.4M -$107K -1,160 -6%
SIA
65
Sit Investment Associates
Minnesota
$1.31M +$1.46M +15,755 New
MLICM
66
Metropolitan Life Insurance Company (MetLife)
New York
$1.3M – – –
NFA
67
Nationwide Fund Advisors
Ohio
$1.27M +$37.4K +404 +3%
Alyeska Investment Group
68
Alyeska Investment Group
Illinois
$1.18M +$1.32M +14,249 New
SM
69
Sabby Management
Florida
$1.12M +$1.25M +13,538 New
State Board of Administration of Florida Retirement System
70
State Board of Administration of Florida Retirement System
Florida
$1.1M +$181K +1,960 +17%
AIG
71
American International Group
New York
$1.08M +$29K +314 +2%
ARC
72
Absolute Return Capital
Massachusetts
$1.07M +$1.19M +12,875 New
Morgan Stanley
73
Morgan Stanley
New York
$922K -$1.88M -20,292 -65%
QIM
74
Quantitative Investment Management
Virginia
$879K +$980K +10,600 New
VOYA Investment Management
75
VOYA Investment Management
Georgia
$876K – – –
1 2
3
4 5

GEVA Hedge Fund Activity: Q1 2014 in Review

115 of the 3,464 institutional investors tracked by Wall St. Rank reported a position in SYNAGEVA BIOPHARMA CORP COM STK (DE) (GEVA) for Q1 2014, worth a combined $2.68B — up 35% from $1.98B a quarter earlier.

Buyers outnumbered sellers: 39 funds opened new GEVA positions and 7 closed out — a net gain of 32 holders — while 41 added to existing stakes and 28 trimmed.

The largest buyer was Capital World Investors, adding an estimated $44.7M. The largest seller was Fidelity Investments, cutting an estimated $32.4M.

  • 115 institutional investors held SYNAGEVA BIOPHARMA CORP COM STK (DE) (GEVA) as of Q1 2014, up from 84 in Q4 2013.
  • Funds reported $2.68B of SYNAGEVA BIOPHARMA CORP COM STK (DE) stock for Q1 2014, up 35% quarter-over-quarter.
  • 39 funds opened new SYNAGEVA BIOPHARMA CORP COM STK (DE) positions in Q1 2014 and 7 closed out, a net change of +32 holders.
  • The largest SYNAGEVA BIOPHARMA CORP COM STK (DE) buyer in Q1 2014 was Capital World Investors, an estimated $44.7M added.
  • The largest SYNAGEVA BIOPHARMA CORP COM STK (DE) seller in Q1 2014 was Fidelity Investments, an estimated $32.4M sold.

Based on aggregated 13F filings for Q1 2014.